Brought to you by:
-
IN.PACT AV DCB sustained ‘superior’ effectiveness in subgroups with high reintervention rates out to two years
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of target lesion primary patency (TLPP) compared to those who underwent standard percutaneous transluminal angioplasty (PTA) through 24 months, investigators behind the IN.PACT AV Access study have reported. Principal investigator Robert Lookstein, MD,…
-
VIVA 2021: IVL ‘consistently’ treats real-world calcium in multiple peripheral vessel beds
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL) performs “consistently well” across challenging peripheral vessels, lesions and subgroups of patients, Ehrin J. Armstrong, MD, medical director at Adventist Heart and Vascular Institute in St. Helena, California, told a clinical trials late-breaking session at Vascular Interventional Advances (VIVA) 2021…
-
Aortic aneurysms, asymptomatic carotid stenosis, Midwestern Vascular Surgical Society, MVSS, vascular consults
Vascular surgeons found to ask twice as many closed- versus open-ended questions in patient encounters
Patients reported they mostly felt their provider was adequate in terms of engaging in shared decision-making during asymptomatic vascular consults, according to a qualitative analysis carried out at the University of Iowa in Iowa City. Furthermore, vascular surgery compared favorably to other specialties across several aspects of interaction, researchers responsible for the study discovered. Nevertheless,…
-
Study detects no difference in adverse outcomes from balloon dilatation strategy used during TCAR
Avoiding a strategy of post-stent balloon dilation during transcarotid artery revascularization (TCAR) may be unnecessary—a “contradistinction” to results shown in conventional transfemoral carotid artery stenting, new research has shown. Jones Thomas, MD, an integrated vascular surgery resident at University Hospitals Cleveland Medical Center in Cleveland, Ohio, and colleagues analyzed data garnered from the ROADSTER trials,…
-
Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy
Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results from the RANGER II SFA randomized controlled trial have demonstrated, investigators revealed during a late-breaking session at Vascular Interventional Advances (VIVA) 2021 (Las Vegas, Oct. 5–7). Principal investigator Ravish Sachar, MD, an interventional…
-
VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom from clinically driven TLR’ in patients with complex lesions
Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion (CTO), long lesion and de novo in-stent restenosis (ISR) cohorts “continues to confirm long-term clinical safety and effectiveness” of the IN.PACT Admiral (Medtronic) drug-coated balloon (DCB) in the treatment of complex…
-
Cuts to Medicare: ‘As vascular disease complexity increases, reimbursement for complex care decreases’
Outgoing Midwestern Vascular Surgical Society (MVSS) President Kellie Brown, MD, has seen fundamental changes to the way vascular surgery is practiced during her 20 years as a surgeon. The advance of endovascular techniques. The arrival of the electronic medical record (EMR). An increasing move toward quality metrics. She has also borne witness to the challenges…
-
AI and transforming vascular surgery
The 2021 Vascular Annual Meeting (VAM) Roy Greenberg Distinguished Lecture saw delegates hear about the potential for artificial intelligence (AI) to transform vascular surgery. Elsie Gyang Ross, MD, assistant professor of surgery at Stanford University, told attendees during her Aug. 19 talk: “We have the ability to shape how this technology can be used to…
-
Save the date for new PAD skills workshop
September is National PAD Awareness Month, and the Society for Vascular Surgery (SVS) will spend the month not only calling attention to causes and treatment for the disease, but also planning a peripheral arterial disease (PAD) skills workshop. The hands-on workshop, aimed at practicing surgeons, includes more than 10 hours of didactics, small-group sessions and…
-
VAM 2021 structural changes prove hit with attendees
It was an epic return: nearly 700 abstracts presented in six plenaries and several other forums; six concurrent sessions; six SVS breakfast sessions; three postgraduate courses; six “Ask the Experts” presentations; more than 1,000 in-person professional attendees; nearly 400 livestreaming registrants; 88 exhibitors in 154 booths; three presidents; two presidential addresses; and three annual meetings…